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SUMMARY 
Twenty eight chronic schizophrenics were assigned in a double blind fashion to treatment with penfluridol 
or placebo for a period of 12 weeks. The clinical picture including the side effects were monitored regularly, 
whenever the clinical picture deteriorated haloperidol in individually adjusted doses was added to the treatment 
regimen. By the end of the study 12 out of the 14 placebo patients required haloperidol as compared to only 1 of 
the 14 penfluridol patients. Evaluation of the results showed no significant differences between the two groups or 
between the baseline and the final ratings in each group. This trial has confirmed the previous reports that 
penfluridol is a suitable drug for maintenance therapy in schizophrenic patients. 
Introduction 
The value of neuroleptic medication 
in preventing schizophrenic patients from 
relapsing has been well documented 
(Davis 1975). Patients on maintenance 
therapy who take neuroleptics irregularly 
are particularly at high risk for psychotic 
decompensation (Groves and Mandell 
1975). Successful maintenance drug treat-
ment of chronic schizophrenia is often li-
mited by patient non-compliance. In addi-
tion to the intrinsic limitations on com-
pliance stemming from the illness itself, 
difficulties result from the necessity of 
daily and often multiple daily drug inges-
tions. 
This problem has led to the search for 
longer acting drugs. The initial approach 
was to use depot injectable preparations of 
fluphenazine. However, injections are 
often fraught with drawbacks and this led 
to the search for long-acting orally ad-
ministered neuroleptics, resulting in the 
discovery and use of diphenylbutyl-
piperidine group of drugs. On these, the 
longest acting is penfluridol (Lapierre 
1978). 
Penfluridol is a potent, long-acting or-
ally effective neuroleptic drug (Janssen 
1970) which safely controls schizophrenic 
symptoms when administered on a weekly 
basis (Van Praag et al 1971; Donlon and 
Ellen Meyer 1978). Side effects may occur 
during the first 2 days, but they are very 
mild and can be controlled with antipar-
kinsonian agents (Tanghe and Verecken 
1972). 
In the present study the efficacy and 
safety of penfluridol as a maintenance 
therapy was evaluated double blind in 
chronic schnizophrenic patients who previ-
ously had been successfully maintained 
with other neuroleptics for at least 6 
months. 
Material and Methods 
The subjects for this study were 30 pa-
tients diagnosed as chronic schizophrenics 
(DSM III) attending the Occupational 
Therapy and Rehabilitation department of 
the National Institute of Mental Health 
and Neurosciences (NIMHANS), Banga-
lore. All of them required maintenance 
neuroleptic therapy for control of 
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continued symptoms and had been so 
stabilised for at least 6 months before entry 
into the study. All the subjects were in 
good general health. The purposes and pro-
cedures and the risks involved were 
explained to each subject and a responsible 
relative and written informed consent was 
obtained before being admitted to the study. 
The patients were assigned to either 
penfluridol or placebo group on a double 
blind basis. As Table 1 indicates the two 
groups were comparable with respect to age, 
sex, duration of illness and the amount of 
neuroleptic medications (in mg % Chlor-
promazine equivalants per day) received. 
Table 1 
Characteristics of the two groups 
Penfluridol Placebo 
Number of patients 14 14 
Sex : Male 7 9 
Female 7 5 
Mean age in years 36.35 35.73 
Mean duration of 
illness in years 10.64 11.56 
Baseline medication 
CPZ mg. equiv./day 290 305 
The patients were abruptly transfer-
red from the previous medication and 
started on the trial medication. All the pa-
tients received identical capsules once a 
week. The dosage of penfluridol was 20 mg 
in the first week, 40 mg in the second week 
and 60 mg / week from the 3rd to the 12th 
week. Whenever during this study the clin-
ical picture of a patient deteriorated 
Haloperidol tablets were added to the 
therapy at an individually adjusted dose. 
This was necessary on ethical grounds be-
cause the study design would otherwise 
mean abrupt withdrawal of maintenance 
neuroleptics medication in half the number 
of paitents participating in the study. No 
other medication was administered during 
the entire 12 weeks study period except 
Trihexyphenidyl hydrochloride to control 
extrapyramidal symptoms. 
The instruments used to evaluate the 
efficacy and the side effects were the Scale 
for Assessment of Negative Symptoms 
(Andreasen 1981), the Scale for Assess-
ment of Positive Symptoms (Andreasen 
1985) and Simpson and Angus (1970) Rat-
ing Scale for Extrapyramidal side effects. 
The patients were rated on the above 
scales at baseline (just prior to admission 
to the study) and weekly thereafter till the 
completion of the study. Baseline and 
weekly records of body weight, pulse rate, 
blood pressure (standing and lying down) 
and clinical laboratory tests e.g: blood 
chemistry, haematology and urine analysis 
were maintained. 
T-test (unpaired) was used for bet-
ween-group comparisons. For within-
group comparisons paired t-test was used. 
Results 
Two patients, one from each group 
dropped out before the completion of the 
study. One from the penfluridol group 
dropped out due to relapse of schizop-
hrenia and rapid decompensation despite 
supplemental haloperidol. The one from 
the placebo group withdrew the consent 
and therefore had to be dropped out of the 
study. Thus 28 patients, i.e., 14 in each 
group were left for the final analysis. 
Excluding the drop outs only 1 patient 
in the penfluridol group required supple-
mental haloperidol while 12 among the 
placebo group did. This indicates a significa-
nt difference in favour of penfluridol (p< 
0.042) proving that maintenance therapy 
with penfluridol is superior to placebo. 
Since penfluridol 60 mg per week is 
equivalent to haloperidol 15 mg per day 
the patients receiving haloperidol were S.M. CHANNA BASAVANNA & ALBERT MICHEAL  335 
divided into 3 groups viz., those receiving 
less than 15 mg per day, 15 mg per day and 
more than 15 mg per day. This data and the 
dosage schedule of penfluridol are shown 
in Table 2. In the haloperidol less than 15 
mg per day group, one patient belongs to 
the penfluridol group. In fact this patient 
needed only 5 mg of supplemental 
haloperidol for control of symptoms. 
Table 2 
Dosage of Penfluridol and Haloperidol by week of 
study 
No. of patients on 
Haloperidol 
Week Pemfluridol* 
Less than ISmg/ 
ISmg/day day 
More than 
15mg/day 
1 20mg/week 
2 40mg/week 
3-12 60mg/week  l* + 4@ 5@  3@ 
•Penfluridol group  ©Placebo group 
Table 3 demonstrates the number of 
patients in each group started on 
haloperidol and the week of the trial it was 
done. This shows that most of the patients 
on placebo had shown signs of relapse in 
the initial phase itself. 
Table 3 
Starting of Haloperidol 
Week of trial 
3 
4 
5 
6 
Total No. of 
patients on 
Haloperidol 
Placebo group 
N=14 
6 
4 
1 
1 
12 
week wise 
Penfluridol group 
N=14 
0 
0 
0 
1 
1 
No significant differences were found 
between the two groups in any of the 
baseline evaluations. A comparative 
analysis of the data showed that the two 
agents were equally effective in controlling 
the schizophrenic symptoms. 
In general both penfluridol and 
haloperidol were well tolerated. No seri-
ous adverse effects were encountered and 
those present were typical of the com-
monly used neuroleptics. Persistant ex-
trapyramidal side effects required daily an-
tiparkinsonian medication in 5 patients of 
the placebo group. Even though 6 patients 
of the penfluridol group required antipar-
kinsonian drugs none of them required it 
for more than 3 days a week. This finding is 
consistent with the previous reports that 
the extrapyramidal side effects of 
penfluridol are short lasting in spite of the 
long therapeutic action. 
The general physical condition and 
the laboratory values were unaffected 
throughout the study period. 
Discussion 
The present study confirms and cor-
roborates the previous investigations indi-
cating that once a week oral administration 
of penfluridol provides adequate and safe 
control of chronic schizophrenia. The 
higher number of patients needing 
haloperidol in the placebo group clearly 
demonstrates that penfluridol is superior 
to placebo. It has also been shown that 
penfluridol maintains the level of improve-
ment previously achieved by long acting 
injectable and short acting oral neurolep-
tics. Compared to haloperidol, penfluridol 
is equally efficacious but necessitates an-
tiparkinsonian medication for a fewer days. 
Thus penfluridol is a safe and effective 
long acting oral neuroleptic for mainte-
nance therapy in schizophrenia. The ad-
vantage is that the patients can avoid the 
discomfort of daily oral medication and 
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family members to better supervise the 
medication regimen. All these factors 
would contribute to better compliance and 
a more successful maintenance drug treat-
ment of chronic schizophrenia. 
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